29840-56-0

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 5-aminopentanoate hydrochloride is used as a reactant for the synthesis of several compounds with therapeutic potential. Its role in the pharmaceutical industry is crucial, as it can be transformed into various active pharmaceutical ingredients (APIs) that target different medical conditions.
Used in Chemical Synthesis:
In the field of chemical synthesis, Methyl 5-aminopentanoate hydrochloride is utilized as a building block for creating a wide range of chemical products. Its versatile structure allows for further functionalization and modification, making it a valuable component in the development of new materials and compounds with specific applications.
Used in Research and Development:
Methyl 5-aminopentanoate hydrochloride is also employed in research and development settings, where it is used to explore new chemical reactions and pathways. Its reactivity and structural features make it an attractive candidate for studying various chemical processes and mechanisms, ultimately contributing to the advancement of scientific knowledge in the field.

InChI:InChI=1/C6H13NO2.ClH/c1-9-6(8)4-2-3-5-7;/h2-5,7H2,1H3;1H

Upstream product

• 67-56-1 methanol 
• 660-88-8 5-aminopentanoic acid 
• 77-76-9 2,2-dimethoxy-propane 
• 627-95-2 5-amino-valeric acid ; hydrochloride 
• 56-12-2 4-amino-n-butyric acid 
• 675-20-7 piperidin-2-one 

Downstream Products

• 94887-45-3 methyl N-retinylidene-δ-aminovalerate hydrochloride 
• 251456-81-2 methyl 5-(4-dimethylaminobenzoyl)aminovalerate 
• 913338-69-9 5-[2-(3-acetoxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-propionylamino]-pentanoic acid methyl ester 
• 727736-40-5 methyl 5-({[2-(benzyloxy)ethoxy]acetyl}amino)pentanoate 
• 383669-14-5 methyl 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]amino]pentanoate 
• 1045792-85-5 methyl 5-[5-(3-tert-butoxycarbonylaminophenyl)-3-isoxazolecarboxamido]pentanoate 
• 1045792-89-9 methyl 5-[5-(4-tert-butoxycarbonylaminophenyl)-3-isoxazolecarboxamido]pentanoate 
• 1144510-78-0 5-(3-((5-fluoro-2-oxoindolin-3-ylidene)methyl)benzamido)pentanoic acid methyl ester 
• 27219-07-4 5-(N-tert-butyloxycarbonyl)aminopentanoic acid 

Relevant academic research and scientific papers

Metadynamics for perspective drug design: Computationally driven synthesis of new protein-protein interaction inhibitors targeting the EphA2 receptor

Metadynamics (META-D) is emerging as a powerful method for the computation of the multidimensional freeenergy surface (FES) describing the protein-ligand binding process. Herein, the FES of unbinding of the antagonist N-(3α-hydroxy-5β-cholan-24-oyl)-L-β-homotryptophan (UniPR129) from its EphA2 receptor was reconstructed by META-D simulations. The characterization of the free-energy minima identified on this FES proposes a binding mode fully consistent with previously reported and new structure-activity relationship data. To validate this binding mode, new N-(3α-hydroxy-5β-cholan-24-oyl)-L-β-homotryptophan derivatives were designed, synthesized, and tested for their ability to displace ephrin-A1 from the EphA2 receptor. Among them, two antagonists, namely compounds 21 and 22, displayed high affinity versus the EphA2 receptor and resulted endowed with better physicochemical and pharmacokinetic properties than the parent compound. These findings highlight the importance of free-energy calculations in drug design, confirming that META-D simulations can be used to successfully design novel bioactive compounds.

Effect of mofezolac-galactose distance in conjugates targeting cyclooxygenase (COX)-1 and CNS GLUT-1 carrier

Neuroinflammation is the earliest stage of several neurological and neurodegenerative diseases. In the case of neurodegenerative disorders, it takes place about 15–20 years before the appearance of specific neurodegenerative clinical symptoms. Constitutive microglial COX-1 is one of the pro-inflammatory players of the neuroinflammation. Novel compounds 3, 14 and 15 (Galmof0, Galmof5 and Galmof11, respectively) were projected, and their synthetic methodologies developed, by linking by an ester bond, directly or through a C5 or C11 unit linker the highly selective COX-1 inhibitor mofezolac (COXs selectivity index > 6000) to galactose in order to obtain substances capable to cross blood-brain barrier (BBB) and control the CNS inflammatory response. 3, 14 and 15 (Galmofs) were prepared in good to fair yields. Galmof0 (3) was found to be a selective COX-1 inhibitor (COX-1 IC50 = 0.27 μM and COX-2 IC50 = 3.1 μM, selectivity index = 11.5), chemically and metabolically stable, and capable to cross Caco-2 cell monolayer, resembling BBB, probing that its transport is GLUT-1-mediated. Furthermore, Galmof0 (3) powerfully inhibits PGE2 release higher than mofezolac (1) in LPS-stimulated mouse BV2 microglial cell line, a worldwide recognized neuroinflammation model. In addition, Fingerprints for Ligands and Proteins (FLAP) was used to explain the different binding interactions of Galmofs with the COX-1 active site.

Oxidative damage of proline residues by nitrate radicals (NO3): A kinetic and product study

Tertiary amides, such as in N-acylated proline or N-methyl glycine residues, react rapidly with nitrate radicals (NO3) with absolute rate coefficients in the range of 4-7 × 108 M-1 s-1 in acetonitrile. The major pathway proceeds through oxidative electron transfer (ET) at nitrogen, whereas hydrogen abstraction is only a minor contributor under these conditions. However, steric hindrance at the amide, for example by alkyl side chains at the α-carbon, lowers the rate coefficient by up to 75%, indicating that NO3-induced oxidation of amide bonds proceeds through initial formation of a charge transfer complex. Furthermore, the rate of oxidative damage of proline and N-methyl glycine is significantly influenced by its position in a peptide. Thus, neighbouring peptide bonds, particularly in the N-direction, reduce the electron density at the tertiary amide, which slows down the rate of ET by up to one order of magnitude. The results from these model studies suggest that the susceptibility of proline residues in peptides to radical-induced oxidative damage should be considerably reduced, compared with the single amino acid.

Compound and application thereof in preparation of medicines for resisting inflammation and treating acute lung injury, chronic obstructive pulmonary disease, asthma or pulmonary fibrosis

The invention provides a compound and application thereof in preparation of medicines for resisting inflammation and treating acute lung injury, chronic obstructive pulmonary disease, asthma or pulmonary fibrosis. The general structural formula of the com

Design and synthesis of Leukotriene A4 hydrolase inhibitors to alleviate idiopathic pulmonary fibrosis and acute lung injury

Idiopathic pulmonary fibrosis (IPF) and acute lung injury (ALI) are considered two severe public health issues, attributed to malfunctions of neutrophils. They can cause chronic inflammation and have association with subsequent tissue damages. There have been rare drugs applying to the efficient treatment in clinical practice. Existing research revealed that Leukotriene B4 (LTB4) is the critical endogenous molecule to induce neutrophil inflammatory response. LTB4 blocking biosynthesis is the potential strategy treating IPF and ALI. In the present study, 45 hydroxamic acid derivatives were produced, and compound 26 was screened out as a highly selective Lead compound of Leukotriene A4 Hydrolase (LTA4H), i.e., an enzyme critical to the biosynthesis of LTB4. This compound is capable of relieving neutrophilic inflammation in an IPF mouse model at early stage, as well as mitigating LPS-induced acute lung injury via a mechanism of LTB4 blocking biosynthesis in vivo. Whether this compound acts as the potential lead compound for the treatment of IPF and ALI requires further verification.

Discovery of a series of selective and cell permeable beta-secretase (BACE1) inhibitors by fragment linking with the assistance of STD-NMR

Two β-secreatase (BACE1) inhibitors from natural products (cinnamic acid and flavone) were linked to furnish potent, cell permeable BACE1 inhibitors with noncompetitive mode of inhibition, with the assistance of saturated transfer difference (STD)-NMR technique. Some of these conjugates also exhibited selective BACE1 inhibition over other aspartyl proteases such as BACE-2 and renin, as well as poor cytotoxicity. Taken together, conjugates 4 represent a new series of BACE inhibitors warrants further investigation for their potential in Alzheimier's disease therapy.

From hit to lead: Structure-based discovery of naphthalene-1-sulfonamide derivatives as potent and selective inhibitors of fatty acid binding protein 4

Fatty acid binding protein 4 (FABP4) plays a critical role in metabolism and inflammatory processes and therefore is a potential therapeutic target for immunometabolic diseases such as diabetes and atherosclerosis. Herein, we reported the identification of naphthalene-1-sulfonamide derivatives as novel, potent and selective FABP4 inhibitors by applying a structure-based design strategy. The binding affinities of compounds 16dk, 16do and 16du to FABP4, at the molecular level, are equivalent to or even better than that of BMS309403. The X-ray crystallography complemented by the isothermal titration calorimetry studies revealed the binding mode of this series of inhibitors and the pivotal network of ordered water molecules in the binding pocket of FABP4. Moreover, compounds 16dk and 16do showed good metabolic stabilities in liver microsomes. Further extensive in vivo study demonstrated that 16dk and 16do exhibited a dramatic improvement in glucose and lipid metabolism, by decreasing fasting blood glucose and serum lipid levels, enhancing insulin sensitivity, and ameliorating hepatic steatosis in obese diabetic (db/db) mice.

Synthesis and antiradical activity of novel copper(II) complexes of long chain reduced Schiff base ligands

Abstract: Oxidative stress is the cause of many diseases and at the heart of it is the overproduction of reactive oxygen species (ROS). There are several protective enzymes, e.g., superoxide dismutases (SOD), able to decrease the level of ROS in the cell; however, a therapeutic use of these enzymes is problematic. Small molecule compounds and complexes able to scavenge free radicals such as superoxide anion radicals could be used instead. These compounds are often called SOD-mimics and various researches are interested in synthesis and study of these compounds. In our study, a series of Cu(II) complexes were synthesized, containing reduced Schiff base ligands prepared from salicylaldehyde and amino acids with longer chain length (5-aminopentanoic acid, 6-aminohexanoic acid, 8-aminooctanoic acid, 11-aminoundecanoic acid, and 12-aminododecanoic acid). Complexes prepared from these ligands are novel and were prepared using three different methods. An assay based on the ability to inhibit reduction of iodonitrotetrazolium dye by superoxide anion radicals was used to determine antiradical activity of the prepared complex. Most of the prepared complexes proved to be good antiradical agents compared to cystamine and the copper(II) complex with Schiff base type ligand N-salicylidene-β-alanine. The best IC50 values of the radical transfer of the prepared compounds were two complexes of N-(2-hydroxybenzyl)-11-aminoundecanoic acid: 97.0?±?1.9 and 45.1?±?0.5?μM. Graphical abstract: [Figure not available: see fulltext.].

Synthesis and hyperpolarisation of eNOS substrates for quantification of NO production by 1H NMR spectroscopy

Hyperpolarization enhances the intensity of the NMR signals of a molecule, whose in vivo metabolic fate can be monitored by MRI with higher sensitivity. SABRE is a hyperpolarization technique that could potentially be used to image nitric oxide (NO) production in vivo. This would be very important, because NO dysregulation is involved in several pathologies, including cardiovascular ones. The nitric oxide synthase (NOS) pathway leads to NO production via conversion of L-arginine into L-citrulline. NO is a free radical gas with a short half-life in vivo (≈5?s), therefore direct NO quantification is challenging. An indirect method – based on quantifying conversion of an L-Arg- to L-Cit-derivative by 1H NMR spectroscopy – is herein proposed. A small library of pyridyl containing L-Arg derivatives was designed and synthesised. In vitro tests showed that compounds 4a–j and 11a–c were better or equivalent substrates for the eNOS enzyme (NO2? production?=?19–46?μM) than native L-Arg (NO2? production?=?25?μM). Enzymatic conversion of L-Arg to L-Cit derivatives could be monitored by 1H NMR. The maximum hyperpolarization achieved by SABRE reached 870-fold NMR signal enhancement, which opens up exciting future perspectives of using these molecules as hyperpolarized MRI tracers in vivo.

MOFEZOLAC DERIVATIVES AS MULTI-FUNCTIONS SELECTIVE COX-1 INHIBITORS

The invention relates to a new class of compounds of formula (I) targeting COX-1. The invention also relates to the use of some of such compounds as a tool to investigate the structure and function of the enzyme, in the treatment targeting COX-1 or detect